ArticleJTO clinical and research reports2024

Efficacy and Safety of Anti-Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Antibodies Plus Chemotherapy as First-Line Treatment for NSCLC in the People's Republic of China: a Systematic Review and Meta-Analysis.

Qi-An Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.